Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
160.00    0.00 (0.00%)
Bid:
157.50
Ask:
160.00
Spread: 2.50 (1.587%)
Market Cap: £1.38b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Friday broker round-up UPDATE

Fri, 14th Mar 2014 09:07
Barclays: Nomura reduces target price from 305p to 285p staying with its buy recommendation. Investec lowers target price from 305p to 295p and keeps its buy recommendation.Ferrexpo: Westhouse Securities increases target price from 190p to 220p and reiterates a buy recommendation.F&C Asset Management: Societe Generale shifts target price from 120p to 122p, while downgrading to hold.Fusionex: Panmure Gordon shifts target price from 637p to 638p and maintains a buy recommendation.Future: Numis places both its target price and its buy recommendation under review.Gable Holdings: FinnCap moves target price from 90p to 100p and keeps a buy recommendation.Gulf Keystone Petroleum: Canaccord Genuity cuts target price from 195p to 100p and downgrades from hold to sell.G4S: Jefferies lowers target price from 290p to 280p and stays with its buy recommendation.Hansteen: Jefferies shifts target price from 100p to 105p retaining a hold recommendation.Home Retail Group: Citi moves target price from 205p to 215p and keeps a neutral rating. Societe Generale ups target price from 175p to 200p, but still recommends selling.Hutchison China MediTech: UBS raises target price from 820p to 1000p, but downgrades from buy to neutral.IMI: Societe Generale increases target price from 1530p to 1690p upgrading to buy.Kazakhmys: Investec raises target price from 158p to 294p and upgrades to hold.Legal & General Trust: Credit Suisse moves target price from 240p to 250p and keeps a neutral rating.Mears Group: Jefferies ups target price from 435p to 485p and keeps a hold recommendation.Moneysupermarket: Westhouse Securities shifts target price from 220p to 223p, while downgrading from buy to add.Morrison (Wm): Nomura lowers target price from 280p to 270p maintaining its buy recommendation. Citi cuts target price from 250p to 220p and retains a neutral rating.Northgate: Barclays ups target price from 449p to 540p, but downgrades to equal-weight.Pearson: Nomura cuts target price from 980p to 950p retaining a reduce rating.Perform Group: Credit Suisse takes target price from 246p to 290p, while downgrading to neutral.Prudential: Deutsche Bank increases target price from 1490p to 1600p leaving its buy recommendation unchanged. Goldman Sachs ups target from 1580p to 1600p and retains its strong buy recommendation.Rightmove: Investec raises target price from 2500p to 2612p and keeps a hold recommendation.Rotork: Societe Generale initiates with a target price of 2725p and a hold recommendation.Royal Dutch Shell: Societe Generale raises target price from 2400p to 2500p and retains a hold recommendation.Sainsbury: Citi reduces target price from 425p to 350p, while its buy recommendation remains unchanged.SIG: Jefferies raises target price from 180p to 220p and maintains its hold recommendation.Tesco: Citi cuts target price from 320p to 300p and maintains a neutral rating.Tribal Group: WH Ireland moves target price from 265p to 275p and maintains a buy recommendation.Trinity Mirror: Numis ups target price from 265p to 280p and keeps a buy recommendation.Weir Group: Investec downgrades from add to sell with a target price of 2250p.

Related News

Credit Agricole's Caceis UK censured, pays $42 million to WealthTek clients
32 mins ago

Credit Agricole's Caceis UK censured, pays $42 million to WealthTek clients

* Caceis UK takes voluntary WealthTek contributions ​to £57 million

Hutchmed China reports positive phase two fanregratinib study data
4 hours ago

Hutchmed China reports positive phase two fanregratinib study data

(Alliance News) - Hutchmed China Ltd on Thursday reported positive phase two data for fanregratinib in patients with intrahepatic cholangiocarcinoma, ...

Hutchmed News

Hutchmed China reports positive phase two fanregratinib study data
4 hours ago

Hutchmed China reports positive phase two fanregratinib study data

(Alliance News) - Hutchmed China Ltd on Thursday reported positive phase two data for fanregratinib in patients with intrahepatic cholangiocarcinoma, ...

Hutchmed highlights data for sovleplenib in rare blood disorder
12 Jun 2026

Hutchmed highlights data for sovleplenib in rare blood disorder

(Alliance News) - Hutchmed China Ltd on Friday said phase III trial results for its investigational drug sovleplenib showed significant efficacy and a...

TRADING UPDATES: Tungsten secures loan; Ashtead trading in line
21 May 2026

TRADING UPDATES: Tungsten secures loan; Ashtead trading in line

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

EARNINGS AND TRADING: AltynGold reports annual revenue surge
29 Apr 2026

EARNINGS AND TRADING: AltynGold reports annual revenue surge

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

Hutchmed begins phase-three trials of lymphoma therapy in China
23 Mar 2026

Hutchmed begins phase-three trials of lymphoma therapy in China

(Alliance News) - Hutchmed China Ltd on Monday said it had begun phase-three clinical trials of its lymphoma treatment in China.

LONDON BRIEFING: GSK gains Japan nod; Anglo to delist shares in Zurich
23 Mar 2026

LONDON BRIEFING: GSK gains Japan nod; Anglo to delist shares in Zurich

(Alliance News) - GSK makes regulatory progress in Japan for a cancer therapy, Anglo American moves to delist from the Swiss exchange as part of its r...

Hutchmed shares slide as recalls cancer treatment Tazverik
9 Mar 2026

Hutchmed shares slide as recalls cancer treatment Tazverik

(Alliance News) - Hutchmed China Ltd on Monday saw its shares fall after reporting the withdrawal of a cancer medication which it licenses from Ipsen ...